H. Kiyota

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin

T. Satoh, I. Okamoto, K. Okamoto, 2011, International Journal of Clinical Oncology.

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kaoru Tanaka, K. Azuma, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

I. Okamoto, K. Nakagawa, K. Yonesaka, 2010, Lung cancer.

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

J. Watanabe, A. Ono, T. Takahashi, 2014, Cancer Chemotherapy and Pharmacology.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, Y. Tanigawara, 2012, Oncology reports.

[Case of Toxocara canis larva migrans cured by additional treatment with albendazole].

K. Takeda, H. Daga, K. Takamatsu, 2008, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, H. Matsuoka, 2011, Anticancer research.

Clinical relevance of sputum cytology and chest X-ray in patients with suspected lung tumors.

K. Takeda, H. Tada, N. Takifuji, 2008, Internal medicine.